

FORM F

The Growth Enterprise Market (GEM)

Company Information Sheet

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this information sheet, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name : SIIC Medical Science and Technology (Group) Limited

Stock code (ordinary shares) : 8018

This information sheet contains certain particulars concerning the above company (the “Company”) which is listed on the Growth Enterprise Market (“GEM”) of The Stock Exchange of Hong Kong Limited (the “Exchange”). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of 17th June 2002

A. General

Place of incorporation : Cayman Islands

Date of initial listing on GEM : 2nd December 1999

Name of Sponsor(s) : n.a

Names of directors: : *Executive Directors:*

(please distinguish the status of the directors – Executive, Non-Executive or Independent Non-Executive)

Lu Ming Fang	Feng Gen Sheng
Li Wei Da	Zhou Jie
Chen Shu Zi	Ge Wen Yao
Wu Jian Zhuang	

Independent Non-Executive Directors:

Kwok Chin Kung, Robert	Li Ka Cheung, Eric
Lee Ka Sze, Carmelo	

Name(s) of substantial shareholder(s) (as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company : Shanghai Industrial Investment (Holdings) Limited (“SIIC”) owns 100% interest in Shanghai Industrial Investment Treasury Company Limited, which owns 100% interest in Shanghai Investment Holdings Limited. Since Shanghai Investment Holdings Limited is the holding company of Shanghai Industrial Holdings Limited (“SIHL”) and SIHL owns 100% interest in Central Force Investments Limited (“CFI”), SIIC is accordingly deemed to be interested in 399,174,000 shares of the Company, representing approximately 64.38% of the entire issued share capital, through its subsidiaries:

<u>Name</u>	<u>Shares</u>
CFI	372,000,000
SIHL	19,119,000
S.I. Infrastructure Holdings Limited*	4,261,000
SIHL Treasury Limited*	3,238,000
Nanyang Enterprises Limited#	556,000
	399,174,000

**S.I. Infrastructure Holdings Limited and SIHL Treasury Limited are wholly-owned subsidiaries of SIHL.*

#Nanyang Enterprises Limited is a wholly-owned subsidiary of SIIC.

Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company : Shanghai Industrial Holdings Limited

Financial year end date : 31st December

Registered address : P.O. Box 309
Ugland House
South Church Street
George Town
Grand Cayman
Cayman Islands
British West Indies

Head office and principal place of business : 26th Floor, Harcourt House
39 Gloucester Road
Wanchai, Hong Kong

Web-site address (if applicable) : www.siicmst.com

Share registrar : *Principal share registrar and transfer office:*
Bank of Butterfield International (Cayman) Limited
P.O. Box 705
Butterfield House
Fort Street
George Town
Grand Cayman
Cayman Islands

Hong Kong branch registrar and transfer office:
Secretaries Limited
5th Floor, Wing On Centre
111 Connaught Road Central
Hong Kong

Auditors : Deloitte Touche Tohmatsu
Certified Public Accountants
26th Floor, Wing On Centre
111 Connaught Road Central
Hong Kong

B. Business activities

The Company was established by Shanghai Industrial Holdings Limited on 17th September 1999 with an aim to developing into a medical technology enterprise which, through its subsidiaries, primarily focuses on the modernisation and the scientific applications of Chinese medicines. The existing operations of the Group consist of Chia Tai Qingchunbao Pharmaceutical Co., Ltd. 正大青春寶藥業有限公司 (“Hangzhou Qingchunbao”) and Shanghai Jahwa United Co., Ltd. 上海家化聯合股份有限公司 (“Shanghai Jahwa”). Hangzhou Qingchunbao, an indirect 55% owned subsidiary, is principally engaged in the manufacture, distribution and sale of pharmaceutical products based primarily on natural herbal ingredients. Shanghai Jahwa, an indirectly owned associated company, is principally engaged in the manufacture, distribution and sale of a wide range of products including personal care and cosmetics products (including products made from natural herbal ingredients) and household cleaning products. In addition to developing its existing operations, the Group plans to participate in the bio-pharmaceutical and biotechnology industry when opportunities arise.

C. Ordinary shares

Number of ordinary shares in issue : 620,000,000 shares
Par value of ordinary shares in issue : HK\$0.10
Board lot size (in number of shares) : 1,000 shares
Name of other stock exchange(s) on which ordinary shares are also listed : n.a.

D. Warrants

Stock code : n.a.
Board lot size : n.a.
Expiry date : n.a.
Exercise price : n.a.
Conversion ratio : n.a.
(Not applicable if the warrant is denominated in dollar value of conversion right)

No. of warrants outstanding : n.a.

No. of shares falling to be issued upon
the exercise of outstanding warrants : n.a.

E. Other securities

No. of share options granted and outstanding : 38,600,000

Responsibility statement

The directors of the Company (the “Directors”) as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet (“the Information”) and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept fully responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Signed:

Lu Ming Fang, Director

Feng Gen Sheng, Director

Li Wei Da, Director

Zhou Jie, Director

Chen Shu Zi, Director

Ge Wen Yao, Director,
by his lawful attorney Li Wei Da

Wu Jian Zhuang, Director

Kwok Chin Kung, Robert, Director

Li Ka Cheung, Eric, Director

Lee Ka Sze, Carmelo, Director